Aptose Biosciences, Inc.
APTO
APTO was delisted on the 1st of April, 2025.
52 hedge funds and large institutions have $39M invested in Aptose Biosciences, Inc. in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 13 closing their positions.
976% more call options, than puts
Call options by funds: $269K | Put options by funds: $25K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less capital invested
Capital invested by funds: $42.6M → $39M (-$3.6M)
10% less funds holding
Funds holding: 58 → 52 (-6)
21% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 14
46% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SMH
Sanders Morris Harris
Houston,
Texas
|
+$468K |
| 2 |
PM
Precept Management
Dallas,
Texas
|
+$279K |
| 3 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$275K |
| 4 |
AC
Annandale Capital
Dallas,
Texas
|
+$246K |
| 5 |
CC
Carlson Capital
Dallas,
Texas
|
+$202K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$2.73M |
| 2 |
Morgan Stanley
New York
|
-$564K |
| 3 |
Man Group
London,
United Kingdom
|
-$472K |
| 4 |
Millennium Management
New York
|
-$388K |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$347K |
APTO Hedge Fund Activity: Q1 2022 in Review
52 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q1 2022, worth a combined $39M — down 8.5% from $42.6M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of APTO and 7 opened new positions — a net loss of 6 holders — while 14 trimmed existing stakes and 11 added.
The largest buyer was Sanders Morris Harris, adding an estimated $468K. The largest seller was 683 Capital Management, exiting entirely with an estimated $2.73M sold.
- 52 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q1 2022, down from 58 in Q4 2021.
- Funds reported $39M of Aptose Biosciences, Inc. stock for Q1 2022, down 8.5% quarter-over-quarter.
- 7 funds opened new Aptose Biosciences, Inc. positions in Q1 2022 and 13 closed out, a net change of -6 holders.
- The largest Aptose Biosciences, Inc. buyer in Q1 2022 was Sanders Morris Harris, an estimated $468K added.
- The largest Aptose Biosciences, Inc. seller in Q1 2022 was 683 Capital Management, an estimated $2.73M sold.
Based on aggregated 13F filings for Q1 2022.